Sidvim LifeSciences Private Limited

Two minutes of quick reading Pharma Regulatory & IP Insights: Q2 2026 USFDA DMF Trends, 505(b)(2) Value Drivers, and EPO Process Patent Rulings Welcome to the latest Sidvim LifeSciences market briefing . This week, we analyse the Q2 CY 2026 USFDA Type II Drug Master File (DMF) submissions , ongoing legal and regulatory shifts in weight-loss therapies, strategic advantages of the 505(b)(2) pathway, and a landmark European Patent Office (EPO) Board of Appeal decision on chemical process claims . 1. Q2 CY 2026 USFDA Type II Drug Master File (DMF) Submissions Overview Monitoring quarterly DMF filings offers valuable business insights on the generic pipeline and highlights opportunities for API suppliers to provide APIs to formulators targeting upcoming Paragraph IV/NCE-1 filings in the US.  During Q2 2026 (April 1 to June 30, 2026),  243 Type II DMFs  were submitted to the USFDA by 165 companies. Geographic Distribution: China Maintains Volume Lead Over the last 2–3 yea...

Two minutes of quick reading Pharma Regulatory & IP Digest: 2026 CGT Trends, GLP-1 Breakthroughs, and EPO Patent Rulings This comprehensive digest analyses the critical updates impacting generic manufacturers, drug compounders, and IP strategists today. 1. The Competitive Generic Therapy (CGT) Market Race The traditional generic drug market is frequently characterised as a "race to the bottom," with heavy multi-competitor volume often triggering severe price erosions of 80% to 95% . To promote generic development in areas with historically inadequate competition, the FDA utilises the Competitive Generic Therapy (CGT) pathway under the FDA Reauthorisation Act (FDARA) . Securing a CGT designation offers a highly lucrative incentive: 180 days of market exclusivity . However, recent data highlights a stark commercial reality: securing a designation does not guarantee market exclusivity, and capturing the prize requires flawless operational timing . Exclusivity Granted vs...